BSI-045B showed promising results in a Phase 2a trial for atopic dermatitis. Biosion received $40 million upfront fee and 19.9% shares in Aclaris Therapeutics.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
BSI-045B showed promising results in a Phase 2a trial for atopic dermatitis. Biosion received $40 million upfront fee and 19.9% shares in Aclaris Therapeutics.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.